Moderna, Inc. Common Stock (MRNA) Financials
Key financial figures for Moderna, Inc. Common Stock (Q3 2026).
Moderna Q3 2026 revenue rose 29% to $1,313M and it swung to GAAP net income of $162M ($0.38 diluted EPS); full-year revenue growth outlook raised to 15% to 25% from up to 10%. Total revenue was $1,313M versus $1,016M a year earlier (the release states +29%), made up of net product sales of $1,273M and other revenue of $40M; the release attributes the growth primarily to higher COVID vaccine sales in international markets under long-term government partnerships. Revenue was $780M in the U.S. and $533M internationally. GAAP income from operations was $130M versus a $(260)M loss in Q3 2025; net income was $162M versus a net loss of $(200)M, and diluted EPS was $0.38 versus $(0.51). On the outlook: 2026 total revenue growth now expected at 15% to 25% (previously up to 10%), with roughly half from the U.S. and half from international markets; cost of sales about $1.7B including the $0.9B non-recurring litigation settlement charge; R&D about $2.7B (previously about $2.9B); SG&A about $1.0B (unchanged); negligible income tax expense; capital expenditures about $0.2B (previously $0.2B to $0.3B); year-end 2026 cash and investments of about $8.1B to $8.3B (previously $4.7B to $5.2B), excluding additional drawdowns from the roughly $0.9B remaining under the credit facility. Figures are for Q3 2026, as Moderna Inc. reported them.
- Revenue
- $1.3B
- Net Income
- $162M
- EPS
- $0.40
- Total Assets
- $13.5B
- Operating Cash Flow
- -$1.6B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $1.3B | $162M | $0.38 | 9.9% | -$1.6B |
| Q2 FY2026 | $145M | -$782M | -$1.97 | -562.07% | -$563M |
| Q1 FY2026 | $389M | -$1.3B | -$3.40 | -356.81% | -$692M |
| Q4 FY2025 | $678M | -$826M | -$2.11 | -126.4% | $912M |
| Q3 FY2025 | $1.0B | -$200M | -$0.51 | -25.59% | -$880M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.9B | -$2.8B | -$7.26 | -158.13% | -$2.1B |
| FY2024 | $3.2B | -$3.6B | -$9.28 | -123.32% | -$4.1B |
| FY2023 | $6.8B | -$4.7B | -$12.33 | -61.9% | -$3.8B |
Frequently asked questions
What was Moderna Inc.'s revenue last quarter?
Moderna Inc. reported revenue of $1.31 billion for Q3 FY2026, up 29.2% from the same period a year earlier.
Is Moderna Inc. profitable?
Yes. Moderna Inc. reported net income of $162.0 million for Q3 FY2026, a net margin of 12.34% on revenue.
How has Moderna Inc.'s margin trended?
Operating margin was 9.9% in Q3 FY2026, compared with -25.59% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Moderna Inc. generate?
Moderna Inc. generated free cash flow of -$1.61 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Moderna, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.